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A B S T R A C T
Ankylosing spondylitis (AS) is an inflammatory rheumatoid disease categorized within spondyloarthropathies
(SpA) and manifested by chronic spinal arthritis. Several innate and adaptive immune cells and secreted-med-
iators have been indicated to play a role in AS pathogenesis. Considering the limitations of current therapeutic
approaches (NSAIDs, glucocorticoids, DMARDs and biologic drugs), finding new treatments with fewer side
effects and high therapeutic potentials are required in AS. Mesenchymal stem cells (MSCs) with considerable
immunomodulatory and regenerative properties could be able to attenuate the inflammatory responses and help
tissue repair by cell-to-cell contact and secretion of soluble factors. Moreover, MSCs do not express HLA-DR,
which renders them a favorable therapeutic choice for transplantation in immune-mediated disorders.
In the present review, we describe immunopathogenesis and current treatments restrictions of AS.
Afterwards, immunomodulatory properties and applications of MSCs in immune-mediated disorders, as well as
recent findings of clinical trials involving mesenchymal stem cell therapy (MSCT) in ankylosing spondylitis, will
be discussed in detail.
Additional studies are required to investigate several features of MSCT such as cell origin, dosage, admin-
istration route and, specifically, the most suitable stage of disease for ideal intervention.
1. Introduction
Ankylosing spondylitis (AS) is a chronic progressive spinal in-
flammatory arthritis and belongs to the spondyloarthropathies (SpA)
group. Clinical manifestations usually emerge in the third decade of life
[1,2]. AS characteristically affects the sacroiliac joints, axial skeleton,
entheses (tendon or ligament attachments to bone), and extra-skeletal
sites such as the eye [3], bowel [4] and skin [5] can frequently be af-
fected. Inflammation processes associated with AS can lead to bone
erosion, new bone formation, and ankylosis occurring in the spine,
which leads to severe pain, a reduction in spinal mobility and stiffness
[1]. By region, the average prevalence of ankylosing spondylitis per
10,000 individuals has been reported as 16.7 in Asia, 23.8 in Europe,
31.9 in North America, and 10.2 in Latin America [6]. Also, there is
some gender difference in AS patients between continents and coun-
tries. Globally, the gender ratio (male: female) is 2.5:1 [7]. The diag-
nostic approaches for AS include attention to the medical history,
physical exam with Bath Ankylosing Spondylitis Metrology Index
(BASMI), radiographs of the cervical, thoracic, and lumbar spines, ul-
trasound and baseline patient-completed outcome questionnaires like
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath
Ankylosing Spondylitis Functional Index (BASFI) [2,8–11] (Table 1).
It has been suggested that cellular elements and cytokine networks,
especially the interleukin-23 (IL-23)/ IL-17 pathway [12,13], involved
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with innate and adaptive immunity are closely associated with trig-
gering, initiation, and progression of disease inflammation, both acute
and chronic [14]. Current drug therapy options are focused on reducing
inflammation, stiffness, back pain, and disability. These treatments in-
clude non-steroidal anti-inflammatory drugs (NSAIDs), disease mod-
ifying anti-rheumatic drugs (DMARDs) and biologic agents, including
tumor necrosis factor (TNF) and IL-17 A blockers [15,16]. Despite these
therapies reducing inflammation and improving clinical manifestations
and ankylosing spondylitis quality of life (ASQoL), many patients with
ankylosing spondylitis suffer from unresponsive or unbearable side ef-
fects from the drugs [17–20] (Fig. 1).
Given that there is no cure for AS, using stem cells has the promise
to raise hope as a beneficial treatment option. Mesenchymal stem cells
(MSCs) are a kind of stem cells that can revolutionize medicine due to
their multipotent capacity and immunomodulatory properties. These
cells can migrate chemotactically to the site of inflammation and injury,
where they could apply anti-inflammatory and repairing effects
[21–23]. Bone marrow is the primary source for harvesting MSCs;
furthermore, umbilical cord and adipose tissue are the other main
source of these cells. Also, different tissues including lung, periosteum,
synovium, tendon, skeletal muscle, deciduous teeth, and peripheral
blood can be used [24,25]. However, before exploiting MSCs in the
clinic, this new cell-based treatment must be carefully studied for safety
and effectiveness.
In this review, we will discuss the ankylosing spondylitis and me-
senchymal stem cell therapy (MSCT). The first two sections of the
present review cover immunopathogenesis of AS, therapeutic ap-
proaches and their restrictions in AS patients. The review then describes
the immunomodulatory and regenerative properties and applications of
MSCs in different immunological disorders. The final section of this
review will cover recent approval of clinical trials of mesenchymal stem
cells for treating ankylosing spondylitis.
2. Immunopathogenesis of AS
Considering the inflammatory feature of AS, various cells, cyto-
kines, and genes have been investigated to find any association between
AS pathogenesis and immunologic factors.
2.1. HLA-B27
The most studied subject in this context is human leukocyte antigen
B27 (HLA-B27), of which 27:02, 27:03, 27:04 and 27:05 subtypes have
been indicated as the most relevant molecules susceptible to AS. As a
meta-analysis on 8993 AS patients and 19,254 healthy controls showed
relative ratios (RR) of 16.02 for HLA-B27, 1.28 for HLA-B*2702 and
1.14 for HLA-B27*04 in ankylosing spondylitis [26].
There are four main hypothesis associating HLA-B27 to AS
Fig. 1. Mesenchymal stem cells can modulate activation of immune cells involved in the pathogenesis of ankylosing spondylitis.
MSCs express surface molecules such as CD73, CD90, and CD105, but not CD34, CD45, and MHC II, confirmed by flow cytometric analysis. These cells produce many
immunomodulatory molecules such as TGF-β, HLA-G5, PGE2, and IDO in response to inflammatory stimulants (IFN-γ, TNF-α, LPS). These stimulants can affect the
secretion levels of the immunomodulatory molecules and have subsequent effects on the immune regulation. MSCs with the secretion of PGE2 and TGF-β can
decrease proliferation, cytotoxicity, and IFN-γ production activity of NK cells. TGF-β, PGE2, and HLA-G5 are the potent immunomodulatory molecules of MSCs that
can suppress the immune system by inhibition of dendritic cell maturation and induction of Treg cell production. On the other hand, MSCs can inhibit the pro-
liferation and activity of effector T cells such as TH1, TH17, and CTL in the pathogenesis of AS. Also, IDO and PGE2 can induce the switch of M1 macrophages to the
anti-inflammatory (M2) cells. Therefore, MSC therapy would pave the way for developing efficient methods of cell therapy to improve the treatment of AS in future.
MSCs: mesenchymal stem cells; CTL: cytotoxic T lymphocyte; TH: T helper cell; M: macrophage; NK: natural killer cell; Treg: T regulatory cell; DC: dendritic cell; B: B
cell; TNF-α: Tumor necrosis factor alpha; TNFR: TNF-α receptor; IL: interleukin; ILR: interleukin receptor; TLR: Toll-like receptor; TGF-β: transforming growth factor
β; HLA-G5: human leukocyte antigen G5; PGE2: prostaglandin E2; IDO: indolamine; IFN-γ: interferon gamma.
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pathogenesis, as follows.
The first one is “arthritogenic peptide,” which focuses on an aberrant
antigen presentation to TCD8+ cells due to the resemblance of micro-
bial peptides as those presented in joints. This phenomenon is probably
due to mentioned HLA subtypes’ ability to present some intrinsic an-
tigens in two different forms. Therefore, T cell development in thymus
would result in less efficient negative selection; as a consequence there
would be some autoreactive TCD8+ subtypes in circulation able to
recognize HLAB27/autopeptide complexes in the second form of pre-
sentation. The problem will occur when these T cells encounter their
specific microbial antigens (e.g. pLMP2 of EBV) similar to autoantigens
since their attack will be directed toward both foreign and self-antigens.
The second hypothesis is “misfolding theory,” which is in favor of
unfolded protein response (UPR) as AS etiology and blames unusual
conformation and slow folding of the HLA-B27 heavy chain for in-
flammatory responses in joint. Unfolded heavy chains tend to misfold
and accumulate in the endoplasmic reticulum (ER); such accumulation
would induce ER stress and activate the UPR, including activation of
NF-κB transcription factor. NF-κB triggers pro-inflammatory cytokines
production among them IL-23, a major agent involved in AS patho-
genesis.
”Failure in eliminating microbial pathogens” is the other theory based
on HLA-B27 inability to present certain antigens to TCD8+ cells, re-
sulting in microbial survival and sustained inflammation.
Finally “homodimer effect,” in which the α heavy chain, after dis-
sociation from the beta-2-microglobulin light chain (B2m), binds to its
homolog molecule and generates a homodimeric HLA-B27 molecule,
which is assumed to be a ligand for KIR3DL2 on TCD4+ and natural
killer (NK) cells. These cells together with T cells with δγ T-cell receptor
(δγ T), T helper 17 (TH17) cells, natural killer T (NKT) cells,
TCD4−CD8− and mast cells are supposed to produce IL-17, the key
player in promoting inflammatory responses in AS. Moreover, KIR3DL2
binding to B27 homodimer inhibits activation-induced cell death
(AICD) driven by TCR/NK interactions, promoting the survival of pa-
thogenic Th17 and NK cell subsets in circulation [27,28].
2.2. Cytokines
As mentioned above, IL-23 is a prominent cytokine with elevated
serum levels and is involved in chronic inflammation of AS, which
triggers IL-22 and IL-17 production. Among IL-23 receptors, rs1004819,
rs1495965, and rs2201841 have been demonstrated to be significantly
higher in AS patients (p-value< .001,< .001,= .010, respectively)
[29,30]. AS pathogenesis is also linked to the proinflammatory cyto-
kines IL-1 and IL-6, as IL-1 SNPs rs2856836, rs17561, rs1894399,
rs3811581, and rs1800587 were found to be significantly increased in
Europeans with AS [31,32]. Moreover, TNF-α is overexpressed in AS
patients’ mononuclear cells, and its inhibition has been applied as a
therapeutic tool in the clinic which will be discussed later [33].
2.3. B lymphocytes
The contribution of B cells to AS has been defined as highly ex-
pressing HLA-B27 antigen presenting cells, as well as autoantibody-
producing plasma cells. In addition, decreased number of CD27+
memory B cells and increased proportion of CD27− naïve B population,
together with a higher percentage of CD86+ B cells, have been de-
monstrated in the peripheral blood of AS patients, suggesting an ex-
cessive activation of these cells at least in relapse phase [34]. In another
study, it was shown that although CD24+CD38+ B regulatory (Breg)
cells’ percentage is similar to healthy controls, their suppressive func-
tion is significantly reduced due to defective IL-10 production [35].
2.4. T lymphocytes
T helper 1 (Th1) and Th17 cells have been suggested as playing a
considerable role in the pathogenesis of AS. Compared to healthy in-
dividuals, ratios of Th1/Th2 and Th17/ T regulatory (Treg) cell are
significantly greater in patients with AS. These imbalanced ratios are
accompanied by excessive interferon gamma (IFN-γ) and IL-17 A cyto-
kines production [36]. Foxp3+ Treg cells number is also decreased in
peripheral blood of AS patients and these cells responsiveness to IL-2 is
diminished. Tregs isolated from patients with active AS are not able to
inhibit T cells proliferation properly [37].
2.5. Dendritic cells, macrophages, and NK cells
There is a study indicating a significant decrease in circulating
myeloid CD1c-expressing dendritic cells in AS patients, whereas CD14−
CD16+ mononuclear cell frequency was increased. The latter group is
supposed to augment Th17 cells’ inflammatory activities through IL-6
secretion [38].
CD163+ macrophages, CD68+ macrophages, and osteoclasts have
also been detected in peripheral arthritis, as well as sacroiliitis lesions
of AS patients. In addition, depletion of macrophages has had anti-in-
flammatory effects in animal models [14].
The CD56dim CD16+ subset of NK cells have increased levels in
ankylosing spondylitis patients’ circulation; these cells express con-
siderable amounts of carcinoembryonic antigen-related cell adhesion
molecule 1 (CEACAM-1) on their surface, facilitating their tissue en-
trance. Increased number of NK cells is correlated with BASDAI score of
disease [39].
2.6. ERAP
Peptide trimming enzyme, endoplasmic reticulum aminopeptidase 1
(ERAP-1) should be added to the list of immune components involved
in AS, owing to the fact that certain SNPs of ERAP-1 are associated with
HLA-B27-induced risk of developing ankylosing spondylitis. The SNPs
rs30187 (OR=1.255), rs27044, rs10050860, rs2287987, rs17482078,
and rs26653 in a meta-analysis of 19,902 AS patients and 39,750
controls have been demonstrated to increase the susceptibility to AS
[40]. Impaired ERAP-1 function in shedding cytokine receptors (e.g.
TNFR, IL-1R2, and IL-6) from cell surface has also been demonstrated in
AS patients [41,42].
3. AS therapeutic approaches and their restrictions
The major purpose of therapy in patients affected with AS is to at-
tenuate inflammation and relieve progressive back pain, morning
stiffness, fatigue, and movement disabilities and as a result, improve
ASQoL [43]. Current AS treatments are widely pharmacological inter-
ventions.
NSAIDs are still the first line of drugs that alleviate preliminary
clinical symptoms of this ailment and dramatically diminish pain and
stiffness of active AS patients [44]. Although long-term consumption of
NSAIDs, particularly in symptomatic active patients, results in pro-
mising effects in slowing spinal radiographic progression [45], some
patients have experienced gastrointestinal and cardiovascular difficul-
ties [46]. Continuous consumption of NSAIDs induce upper gastro-
intestinal ulcers in about one-third of patients, which is diagnosed by
endoscopy [47]. In these cases, selective inhibitors of cyclooxygenase
(COX)-2, such as celecoxib and meloxicam, which have less serious side
effects, should be prescribed [48]. Meanwhile, on the basis of the
Massó-González study, coxibs have less relative risk estimate of gas-
trointestinal bleeding/perforation compared to traditional NSAIDs (OR:
1.88 vs 4.50, respectively) [49].
Cardiovascular disease is stated as the most common cause of
mortality in AS patients. The rate of cardiovascular dysfunction in AS
patients range from 2 to 10%. In at-risk patients with long-term AS,
increased heart morbidity rates are reported [50]. Cardiovascular
events comprising of conduction and rhythm disturbances, valve
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insufficiency (aortic and mitral), myocardial infarction, stroke, is-
chemic heart failure, and acute coronary syndrome, are related to the
chronic inflammatory pathology of AS [51,52]. The relative risk esti-
mate of cardiovascular events in AS patients ranges from 1.0 to 2.0.
Celecoxib-related adverse events increase with high dose regimen of
drug and the background risk of patients [53].
Regarding these drawbacks, NSAIDs should be prescribed cautiously.
Taking this into account, the previous history of gastrointestinal and car-
diovascular risks, the dose and duration of NSAIDs and concomitant use
with other drugs can influence the side effects of NSAIDs [47].
Glucocorticoids are the subsequent suggested medication to sup-
press inflammation and reduce spinal pain in some subjects with a flare-
up of AS symptoms. Glucocorticoids can be taken orally or injected into
affected joints locally [54]. AS patients with concurrent acute anterior
uveitis (AAU) show a good response to this treatment. As a result, both
eye inflammation and expression of IL-17 and IL-23 cytokines reduced
in active AS patients with AAU [55]. However, the long-term use of
glucocorticoids can lead to serious adverse effects, including osteo-
porosis and increased risk of bone fractures, the occurrence of new
infections and weight gain [56,57].
DMARDs are the next group of drugs that have proven to be efficacious
for only peripheral joint involvement and some extra-articular manifesta-
tions, like uveitis and bowel inflammation [44]. Sulphasalazine (SSZ), a
highly effective type of DMARDs, is helpful for dampening symptomatic
arthritis in patients with the more active disease but have no significant
impact on the axial skeleton [20]. Methotrexate (MTX), another conven-
tional DMARD, seem to be less effective in AS in contrast with RA. More-
over, in some patients with persistent joint involvement, combination
DMARDs therapy may be beneficial to manage arthritis [58]. Despite in-
hibiting IL-1 and TNF- α production, sulphasalazine also induce apoptosis of
immune cells. While methotrexate, by inhibiting the enzyme dihydrofolate
reductase, is a purine metabolism inhibitor. Therefore, by increasing ade-
nosine, its inhibitory effects are widely applied [59,60]. Also, DMARDs can
influence the expression and function of ATP-binding cassette (ABC) pro-
teins in the autoimmune diseases [61].
The recent emerging line of therapies is comprised of biologic
agents with beneficial outcomes, particularly anti-TNF-α. TNF-α is a
pro-inflammatory cytokine that is predominantly generated by acti-
vated macrophages and lymphocytes during immune responses [62].
Previous studies demonstrated the elevated amount of TNF-α in AS
subjects, indicating its fundamental role in disease pathogenesis [63].
The use of TNF-α inhibitors is the best choice for patients who poorly
respond to former treatments. Four synthetic anti-TNF-α agents, including
infliximab (Remicade®), adalimumab (Humira®), golimumab (Simponi®)
and the recombinant receptor etanercept (Enbrel®) [64] are currently used
in order to dramatically decrease signs of spinal inflammation and seem to
improve imaging outcomes [65]. In addition to axial manifestations, TNF-α
inhibitors could improve uveitis, peripheral arthritis and bowel inflamma-
tion [66]. Furthermore, TNF-α blockers have shown to down-regulate ESR
and serum level of CRP in active AS patients. They can be more beneficial if
injected in the early phase of disease development [65].
The most important obstacle is that almost 40% of AS patients are
unable to tolerate or respond to conditional medications [67]. In a
proportion of patients with inadequate response to first anti-TNF
therapy, alternative TNF-α inhibitor will be used. Despite switching
TNF-blocking agent, there is still a chance of failure because of drug
inefficacy or possible side effects [18,46].
Another substantial risk of the anti-TNF-α appliance is the recur-
rence of bacterial and fungal infections, especially tuberculosis (TB)
and candidiasis, as a result of suppressing immune responses [17,67].
The incidence rate of these serious infections are low but are severe, or
even fatal, in some cases. Data from a meta-analysis by XU et al. re-
vealed that relative risk of TB in AS patients receiving anti-TNF agents
was 2.42 compared to the control group; however, the ratio was not
significant. TB recurrence was mostly correlated with patients receiving
infliximab, while those receiving etanercept had the less immunogenic
potency to reactivate TB [68]. As about 5–10% of patients with latent
TB infection will ultimately develop to active TB, physicians have to
perform appropriate screening of patients in a timely manner, in terms
of being mycobacteria-infected prior to treatment commencing [69].
In a meta-analysis that carried out in 2016, Wei Liu et al. observed
no significant statistical differences concerning efficacy and safety of
TNF-α inhibitors [70]. The results of short-term follow-up studies in-
dicate little to no difference in the number of patients dealing with
serious infection with various anti-TNF-α drugs compared to subjects
who receive a placebo [71].
Furthermore, TNF-α inhibitors do not guarantee long-term remis-
sion and cessation of therapy, resulting in AS recurrence [18,19].
Withdrawal of anti-TNF therapy leads to relapse within 6–12 months in
almost all patients, requiring re-administration [72].
Unfortunately, TNF-α blockade appears to be unable to halt new spinal
bone formation in progressive AS, although it is not clearly characterized
whether TNF- α is related to structural progression in the spine of AS pa-
tients or not. Several cohort studies proposed that TNF-driven inflammation
may be independent from syndesmophyte formation in AS [73].
In addition to these commonly taken medications, several treat-
ments are being investigated in order to obtain approvals. Certolizumab
pegol (Cimzia®) is a medicine targeting TNF-α function in phase III
axial SpA clinical trial [74,75]. Pathan et al. reported the probable ef-
fectiveness of oral phosphodiesterase 4 inhibitor, apremilast (Otezla®),
in a double-blind phase II study in AS treatment [76].
Secukinumab, a newly discovered monoclonal antibody against IL-17, is
the first approved non-anti-TNF biologic agent and appears to have con-
siderable benefits in patients with weak response to TNF-α blockade [77].
In spite of the fact that patients receiving secukinumab showed improve-
ment rate up to 40%. According to the Assessment of SpondyloArthritis
Society (ASAS), administration of this drug resulted in staphylococcus aureus-
caused abscess in a patient in the secukinumab-treated group [15]. Efficacy,
safety, and tolerability of secukinumab are currently undergoing phase 3
clinical trials. In this randomized 3-year study, the risk of candida infections
and uveitis were reported, but no occurrence of cardiovascular events,
Crohn’s disease or ulcerative colitis [78].
With regard to therapeutic limitations in the current AS treatment
modalities (those containing NSAIDs, glucocorticoids, DMARDs and
biologic drugs), deciphering new medicinal approaches without these
adverse events is essential for efficacious anti-inflammatory therapies.
A promising therapeutic approach for inflammatory disorders and
tissue injuries seems to be mesenchymal stem cell therapy [54,79–81].
Respecting immunomodulatory and regenerative properties of me-
senchymal stem cells, the beneficial effects of MSCT are demonstrated
in several experimental studies [82–84].
4. MSCs; the immunomodulatory and regenerative properties
Mesenchymal stromal or stem cells were first described in 1976. They
are multipotent stromal cells and have a self-renewal proficiency to dif-
ferentiate into various cell types, including osteoblasts, chondrocytes, and
adipocytes [85–87]. MSCs can be acquired from bone marrow, adipose
tissue, umbilical cord, molar cells, amniotic fluid and peripheral blood
[86,88–90]. The frequency ranges of MSCs have been reported in the pre-
vious reports based on CFU-F (fibroblast colony-forming unit) measure-
ment. The CFU-F assay is used for measurement of MSC frequency in dif-
ferent tissues and sites. According to the CFU-F/106 nucleated cells, the
mean value of MSCs originated from bone marrow, adipose tissue, dermis,
umbilical cord blood, peripheral blood, synovial fluid, and amniotic fluid
are 46, 25602, 115500, 0.01, 1, 126, 4.6 respectively [91,92]. These cells
express CD29, CD44, CD73, CD90, CD105, CD106, and CD166, but not
CD11b, CD14, CD34, CD45 nor HLA-DR, confirmed by flow cytometric
analysis in vitro [86,93,94]. MSCs have antioxidative, angiogenic and anti-
inflammatory properties [90,95,96]. These cells can be isolated easily and
are very proliferative in vitro. Additionally, neither local transplantation nor
systemic administration can induce immunoreactivity in the host [97,98].
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Secreted molecules from these cells include hepatocyte growth
factor-1 (HGF-1), transforming growth factor beta (TGF-β), vascular
endothelial growth factor (VEGF), tumor necrosis factor-stimulated
gene-6 (TSG-6), prostaglandin E2 (PGE2), galectin 1 and 9, as well as
MSC-derived microvesicles that play different roles in the host
[90,94,99].
4.1. Immunomodulatory effects of MSCs
MSCs induce a positional inhibitory environment through inhibition by
cell-to-cell contact and soluble factor secretion. Numerous studies have
shown that MSCs possess immunomodulatory effects. Secretion of many
biological molecules and mediators, such as cytokines, from these cells plays
an important role in this process. Human MSCs avoid allorecognition,
prevent the dendritic cell, T-cell and microglia function, and proliferation.
In this process, MSCs can modulate the cytokine secretion of dendritic cells,
macrophages, andmonocytes. Secreted cytokines and factors can induce the
switch of M1 macrophages to the anti-inflammatory cells that in this path,
the role of indolamine (IDO) and PGE2 have been identified. MSCs can
prevent the reactive oxygen species production by neutrophils in in-
flammatory conditions. Furthermore, MSCs have low immunogenicity due
to the absence of cell surface HLA- DR and co-stimulatory molecules such as
CD40, CD80, and CD86. In this way, MSCs can affect immune function of
cells and exert the immunosuppressive effects, and these properties can
confer many therapeutic benefits of MSC transplantation in diseases
[85,98,100–102].
MSCs produce many molecules in response to various stimulants,
such as hypoxia, and inflammatory stimulants (IFN-γ, TNF-α, LPS).
These stimulants can affect the secretion levels of these molecules and
have subsequent effects on the immune regulation [99,102].
4.1.1. The effect of MSCs on NK cells
MSCs can decrease the activity of natural killer cells. NK cells have
important roles in the innate immune response, and the im-
munomodulatory effects of MCS transplantation have been demon-
strated in acute myocardial infarction (AMI) by a decrease of infarct
lesion size [96]. Secretion of PGE2 by MSCs can decrease the pro-
liferation and cytotoxicity activity of NK cells as well as affect CD56
marker expression in these cells [103].
4.1.2. The effect of MSCs on dendritic cells, neutrophils, B and T cells
TGF-β is the potent cytokine to suppress the immune system by in-
hibition of dendritic cell maturation and induction of Treg cell production
[99]. On the other hand, TSG-6 can neutralize the inflammatory effects of
TNF-α and IL-1. PGE2 has suppressive roles in the immune system, in-
cluding inhibiting proliferation and activity of T cell [94,99].
MSCs can inhibit the T cell and B cell activity by direct contact [94],
as well as by having an inhibitory effect on the Tregs through the action
of HLA-G5 and TGF-β secretion [102]. On the other hand, MSCs can
affect the tissue migration of neutrophils by the effect of IDO, TGF-β
and IL-6 secretion [104].
4.2. Regenerative properties of MSCs
MSCs have regenerative roles in many tissues and organs, can dif-
ferentiate into different cell groups including mesodermal, ectodermal,
or endodermal cells, and also have a key role in the tissue repair. It is
believed that multilineage-differentiating stress enduring (Muse) cells
in mesenchymal tissues of adults play an important role in this regard
[105]. On the other hand, MSCs can migrate to the injured tissues and
increase the survival of damaged cells by inhibition of proinflammatory
cytokines secretion. These properties and benefits of MSC transplanta-
tion (MSCT) have been demonstrated in many diseases, such as idio-
pathic pulmonary fibrosis (IPF), cerebral ischemia, acute renal failure,
myocardial infarction, acute lung injury and Alzheimer’s disease
[80,98,106,107].
5. Applications of MSCs in immune-mediated disorders
MSCs have been introduced as a population of adult multipotent
cells that have great potential in immunomodulation and alleviating
multiple kinds of immunological dysfunctions [108]. On the other
hand, the treatment based on MSCs transplantation has a powerful
therapeutic potential for immune-mediated disorders [109]. It is for-
tunate that the patients did not show side effects after the MSC infusion
[110,111]. Herein, we summarize some of the clinical trials of MSC
therapy in different immunological disorders (Table 2).
Recent findings support that MSCs are a promising tool for ameli-
orating the immune dysregulations in patients who are suffering from
immunologic disorders [135]. There is an agreement that MSCs can be
cultured in vitro with no risk of transformation, whereas a few studies
have shown that administered MSCs may have adverse effects [136].
Therefore, the safety profile of this procedure and possible long-
term adverse effects, including uncontrolled proliferative processes and
development of neoplasms, require further thorough examinations
[137]. It seems MSCs can pave the way for future developments of a
successful stem cell therapy for several immune disorders in humans
[138].
6. MSC: MSC therapy in ankylosing spondylitis
The safety and therapeutic potency of MSC therapy have been
shown in many types of research, and also in other disorders such as
SLE, MS and autoimmune diseases [79,102]. Many clinical trials are in
progress about MSC transplantation in related disorders, such as phase
I/II clinical trial to assay the safety and clinical effects of MSC trans-
plantation in AS patients [102,139–141]. As mentioned previously
about MSCs roles in the immune modulation, the transplantation of
these cells is a therapeutic choice in AS patients that cannot tolerate the
anti-inflammatory drugs [139]. In the previous reports, it has been
shown that the number of Treg cells in AS patients are low, as well as
low levels and abnormal function of B cells, with the resulting auto-
antibodies being involved in AS pathogenesis. Additionally, MSCs can
differentiate T cells to the Th2 phenotype and decrease cytokine levels
of Th17 cells due to inhibition of differentiation of these cells, and
therefore, MSC therapy has many benefits for AS patients [140].
Table 1
Advantages and disadvantages of MSCs as a therapeutic option in ankylosing spondylitis.
Advantages Disadvantages
Accessibility (Bone marrow, Adipose, Umbilical cord, …)
Easy to harvest and expand in tissue culture
Immunosuppressive effects (Cell contact, soluble factors secretion)
Multi lineage differentiation (Regenerative effects)
Favorable therapeutic choice for transplantation (HLA-DR−)
Possibility of autograft application
Limited application for aging MSCs
The possibility for malignant transformation
Poor differentiation and short-term activity in vivo
Limited engraftment
Possibility of contamination
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Previous studies have shown that MSC infusion in AS patients is a
safe and beneficial choice with no severe side effects, and is effective in
decreasing the related clinical symptoms and severity of the disease
[139,140]. Wang et al. demonstrated that intravenous infusion of al-
logeneic mesenchymal stem cells is an effective and safe treatment in
active ankylosing spondylitis patients [139]. Also, in a study conducted
by Ai Li et al., the intravenous transfusion of umbilical cord mesench-
ymal stem cells (UC-MSCs) shows beneficial outcomes such as safety
and decrease of clinical symptoms in the AS patients [140]. However,
more studies are necessary regarding the effectiveness of MSC therapy
and the systemic adverse effects of its intravenous injections for curing
of AS patients in the future [139–141]. For this purpose, it is necessary
to study a larger number of patients. Recent studies have been con-
ducted on a smaller number of patients due to the low number of AS
cases, especially in Asia [139,140].
At present, many clinical trials are in progress for curing AS patients
with MSCs (Table 3). In summary, in phase 1 of a clinical trial (Iden-
tifier: NCT01420432), application of human umbilical cord-derived
mesenchymal stem cells (hUC-MSCs) was assessed and repeated after 3
months, along with DMARDs were given to the patients [142]. Another
clinical trial, (Identifier: NCT01709656) involved IV infusion of human
mesenchymal stem cells plus NSAIDs in AS patients [143]. Other
clinical trials, including phase 2 of a clinical trial (Identifier:
NCT02809781) for evaluation of human bone marrow-derived MSCs
application in AS patients [144] and clinical trial phase I/II, registration
number: ChiCTR-TRC-11001417 for safety evaluation of MSC trans-
plantation in AS are in progress [145]. The results of these can help us
to cure AS patients in the future.
7. Conclusion and future perspective
Despite considerable achievements in the treatment of ankylosing
spondylitis using NSAIDs, glucocorticoids, DMARDs and biologic drugs,
a highly efficient therapeutic modality without side effects has not yet
been established. Mesenchymal stem cells with substantial im-
munomodulatory and regenerative properties are a favorable ther-
apeutic choice in treating immune-mediated disorders such as AS. MSCs
can modulate the activation of immune cells associated with the pa-
thogenesis of ankylosing spondylitis and can promote regeneration
process in subsequent tissue damage. The findings of previous studies
demonstrate that injection of MSCs might be beneficial in alleviating AS
signs and symptoms. Nonetheless, further studies are required to in-
vestigate several features of mesenchymal stem cell therapy, such as
cell origin, dosage, administration route and especially the most ideal
stage of disease (early or end) for intervention. Currently, there are
several ongoing clinical trials evaluating the efficacy and safety of
MSCT in AS patients. The results of these studies would pave the way
for developing efficient methods of cell therapy to improve the treat-
ment of AS in future.
Table 2
Clinical trials of mesenchymal stem cell therapy in immune-mediated disorders.







MSCs treatment for GVHD
GVHD grade II- III Bone marrow 2×106/kg 14 I/II 92.9 % Improved N [112]
GVHD grade III-IV Allogeneic placenta (0.9 - 2.8) × 106/kg 9 – 75 % Improved O [113]
GVHD grade III-IV Bone marrow (0.9 - 3) × 106/kg 37 – 65% Improved N [114]
cGVHD grade - Bone marrow (1.3 - 2.7) × 106/kg 7 – 57% Improved N [115]
aGVHD grade II-IV Bone marrow (1.3 - 2.7) × 106/kg 12 – 91.6% Improved N [115]
MSCs prophylaxis for GVHD
Aplastic anemia Allogeneic umbilical cord 5.0× 105/kg 21 – 100% Improved N [116]
Aplastic anemia Allogeneic umbilical cord (2.87 - 10) × 106/kg 17 – 88.2% Improved N [117]
Hematologic malignancy Allogeneic umbilical cord 5.0× 105/kg 50 – 66% Improved N [118]
Hematologic malignancy Bone marrow (1 - 5) × 106/kg 46 I 53% Improved N [119]




63.2×106 cells/patient 15 I/II 79% Mixed O [121]
Multiple sclerosis Allogeneic
bone marrow
3- 5× 107 cells/patient 10 I 50% Mixed O [122]
Multiple sclerosis Allogeneic
bone marrow
1-1.5×106 cells/patient 10 I 60% Mixed N [106]
Multiple sclerosis Autologous
bone marrow
1–2×106/kg 15 II – Improved N [123]
Crohn’s disease Allogeneic
bone marrow
2×106/kg 16 II 80% Improved N [124]
Crohn’s disease Human placenta 2–8× 108/person 12 I – Improved O [125]
Crohn’s disease Autologous
bone marrow
1–2×106/kg 9 I 30% Improved O [126]
Crohn’s disease Autologous adipose 3–30×106/person 5 I – Mixed N [127]
Diabetes Allogeneic placenta 1.35×106/kg 10 I 40% Improved N [128]
Diabetes Autologous
bone marrow
Not clear 41 – 100% Improved N [129]
Systemic lupus erythematosus Allogeneic
bone marrow
1×106/kg 2 – – No change N [130]
Systemic lupus erythematosus Allogeneic umbilical cord
blood
1×106/kg 1 I – Improved N [131]
Systemic lupus erythematosus Allogeneic umbilical cord
blood
1×106/kg 16 I 100% Improved N [132]
Systemic lupus erythematosus Allogeneic
bone marrow
1×106/kg 15 I 86% Improved N [133]
Osteoarthritis Autologous
bone marrow
8-9× 106 4 – 75% Improved N [134]
aGVHD: acute graft versus host disease, cGVHD: chronic graft versus host disease, N: not observed, O: observed.
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